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Introduction
Cancer cells have augmented nutrient transport andmetabolism to cope with their enhanced activities in
cell proliferation and survival [1]. Upregulated nutrient
transporters and metabolising enzymes provide potential
targets for anticancer therapy and diagnosis. For instance,
expression of glucose transporters GLUT (solute carrier
SLC2A subfamily) and hexokinases is increased in most
types of cancer. Both are targets of the glucose analogue
2-deoxy-2-[18F]ﬂuoro-D-glucose ([18F]FDG), the most
frequently applied probe for tumour imaging by positron
emission tomography (PET) [2].
Among the amino acid transporters, LAT1 and LAT3
(SLC7A5 and SLC43A1), ASCT2 (SLC1A5), xCTCorrespondence to: Stefanie D. Krämer; e-mail: stefanie.kraemer@pharma.ethz.ch
Abstract
Purpose: The concentrative amino acid transporter ATB0,+ (SLC6A14) is under evaluation as a
target for anticancer therapy. An ATB0,+-selective positron emission tomography (PET) probe
could advance preclinical drug development. We characterised the cationic tyrosine analogue
O-2((2-[18F]fluoroethyl)methyl-amino)ethyltyrosine ([18F]FEMAET) as a PET probe for ATB0,+
activity.
Procedures: Cell uptake was studied in vitro. ATB0,+ expression was quantified by real-time
PCR. [18F]FEMAET accumulation in xenografts was investigated by small animal PET with
mice.
Results: [18F]FEMAET accumulated in PC-3 and NCI-H69 cancer cells in vitro. As expected for
ATB0,+ transport, uptake was inhibited by LAT/ATB0,+ inhibitors and dibasic amino acids, and
[18F]FEMAET efflux was only moderately stimulated by extracellular amino acids. ATB0,+ was
expressed in PC-3 and NCI-H69 but not MDA-MB-231 xenografts. PET revealed accumulation
in PC-3 and NCI-H69 xenografts and significant reduction by ATB0,+ inhibition. Uptake was
negligible in MDA-MB-231 xenografts.
Conclusion: ATB0,+ activity can be imaged in vivo by PET with [18F]FEMAET.
Key words: ATB0,+, SLC6A14, Positron emission tomography, PET, Tyrosine, Cationic amino
acid, PC-3, NCI-H69, MDA-MB-231, FEMAET
(SLC7A11), and ATB0,+ (SLC4A16) are upregulated in
many cancer types [1, 3]. Figure 1 shows an overview of
their transport characteristics. The amino acid PET probes 6-
[18F]ﬂuoro-L-DOPA ([18F]FDOPA), O-(2-[18F]ﬂuoroethyl)-
L-tyrosine ([18F]FET) and 5-(2-[18F]ﬂuoroethoxy)-L-trypto-
phan ([18F]FEHTP) accumulate in tumour cells via LAT1,
an obligatory exchange system for large neutral amino acids
[1, 4–6]. Besides LAT, also ASCT2 and xCT are exchange
transporters. The ASCT2 substrate [18F]ﬂuciclovine (anti-
[18F]FACBC), a leucine derivative which is currently under
clinical investigation, shows promising characteristics for the
imaging of aggressive prostate cancer [7, 8]. Among these
transporters, only ATB0,+ is unidirectional. It has the unique
property to transport its substrates even against a concentra-
tion gradient from extra- to intracellular. While LAT,
ASCT2 and xCT promote inﬂux of neutral amino acids,
ATB0,+ recognises also cationic besides neutral amino acids
[1].
ATB0,+ overexpression has so far been shown in breast,
colorectal and cervical cancers and cell lines of colon and
breast cancer [1, 9]. Compared to other amino acid transport
systems, it has relatively low expression levels in healthy
tissue. Signiﬁcant expression was detected in lung, trachea,
salivary glands, mammary glands and pituitary gland and
lower levels in colon, uterus, prostate and testis [10, 11].
ATB0,+ is characterised by a broad substrate speciﬁcity,
including D-amino acids. The unidirectional concentrative
transport is driven by transmembrane gradients of sodium
and chloride ions and more generally by the membrane
potential [1, 12]. The transporter is currently under investi-
gation as a drug target for cancer therapy. Inhibition of
ATB0,+ with α-methyl-DL-tryptophan (αMTRP), a LAT and
ATB0,+ inhibitor, resulted in reduction of xenograft size in
nude mice in vivo and autophagy of tumour cells in vitro [9,
13]. Besides direct inhibition for anticancer therapy, the
transporter may be targeted to deliver cytotoxic drugs into
tumour cells. Hatanaka et al. have shown transport by
ATB0,+ of side chain esteriﬁed aspartate (β-carboxyl group)
and glutamate (γ-carboxyl group) [11]. Esteriﬁcation at the
α-carboxyl group or at the side chain hydroxyl group of
amino acids could offer alternative approaches for drug or
pro-drug delivery into tumour cells via ATB0,+ transport [11,
12].
ATB0,+ may thus become a target for multiple approaches
in anticancer therapy. Since not every cancer type has
elevated ATB0,+ levels [9], enhanced ATB0,+ activity by the
primary tumour or metastases needs to be conﬁrmed before
an ATB0,+-targeting therapy is started. Molecular/functional
imaging allows non-invasive quantiﬁcation of regional
expression levels or activities of target proteins. An
ATB0,+-selective PET probe may help evaluating ATB0,+-
targeting drug candidates in vivo in preclinical drug
development programs. It may in addition serve in the
future to recognise ATB0,+-positive tumours to identify
patients who could beneﬁt from anticancer therapy with an
ATB0,+-targeting drug or pro-drug.
In this work, we evaluated our recently introduced cationic
amino acid PET probe O-2((2-[18F]ﬂuoroethyl)methyl-
amino)ethyltyrosine ([18F]FEMAET, Fig. 2) [14] as a substrate
and selective PET probe for ATB0,+. We studied the
characteristics of transport into and out of ATB0,+-expressing
PC-3 prostate cancer and NCI-H69 small cell lung cancer
cells in vitro and chose three cancer models according to their
ATB0,+ mRNA levels as determined by real-time PCR for in vivo
PET studies, namely PC-3 and NCI-H69 as ATB0,+-positive and
Fig. 1. Schematic overview of amino acid transporters. Symbols are explained in the figure. Na++0 indicates Na+-cotransport
with a neutral amino acid. ATB0,+ transport is dependent on Na+/Cl− gradients/membrane potential. ASCT2 transport is Na+
dependent. ATB0,+, LAT1, LAT3, ASCT2 and xCT can be upregulated in cancer cells (references see text). Cell polarisation is
not considered in the figure.
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breast cancerMDA-MB-231 as ATB0,+-negative tumours. These
three tumour models accumulated the LAT1 substrate
[18F]FEHTP under identical experimental conditions [6]. Finally,
we investigated the effect of the ATB0,+ inhibitor αMTRP on
[18F]FEMAET accumulation in NCI-H69 xenografts in vivo
to address the potential of [18F]FEMAET PET to evaluate
ATB0,+-modifying agents in vivo.
Materials and Methods
Radiosynthesis of [18F]FEMAET and In Vitro Cell
Studies
[18F]FEMAET was produced by nucleophilic substitution of a fully
tert-butyl protected chloride precursor, synthesised from L-tyrosine,
with non-carrier-added [18F]KF-K2.2.2 complex in DMSO and
subsequent deprotection as described elsewhere [14]. Speciﬁc
radioactivity was between 28 and 45 GBq/μmol at a radiochemical
purity of 999 %. The stereochemistry of the ﬁnal product was not
investigated. For in vitro and in vivo experiments, [18F]FEMAET
was formulated in phosphate-buffered saline (PBS) containing
10 mg/ml sodium ascorbate (pH 7–8) and 5 % ethanol.
PC-3 and NCI-H69 cells were purchased from the German
Collection of Microorganisms and Cell Cultures, Cell Lines Service
(DSMZ, Braunschweig, Germany) and were cultured according to
the supplier's protocols. Twenty-four hours before a transport assay,
PC-3 cells were seeded at 13,000 cells/cm2 in 48-well plates
(Costar; Corning) and NCI-H69 cells were subcultured in suspen-
sion into fresh medium. One hour before the assay, cells were
washed and incubated at 37 °C with 400 μL Earle's balanced salt
solution (1 mio NCI-H69 cells per tube) containing Ca2+ and Mg2+
(EBSS, Invitrogen) [6].
For uptake studies, 20 kBq [18F]FEMAET was added to each
well or tube (time zero), and cells were incubated at the indicated
temperature on a shaker at 25 rpm (PC-3) or 130 rpm (NCI-H69)
and washed twice with ice cold incubation solution at the indicated
time points. PC-3 cells were detached with 0.25 % trypsin/1 mM
EDTA (Invitrogen); NCI-H69 cells were pelleted by centrifugation
and radioactivity was quantiﬁed in a gamma counter and decay-
corrected (Perkin Elmer Wizard 1480). Protein content of the lysed
cells (2 % sodium dodecyl sulphate) was quantiﬁed in parallel with
the DC Protein Assay (Bio-Rad) and bovine serum albumin as
standard. For inhibition experiments, 10 mM (ﬁnal concentration)
2-amino-2-norboranecarboxylic acid (BCH), 10 mM L-arginine,
10 mM L-lysine, 10 mM L-histidine (PC-3) or 1 mM αMTRP (NCI-
H69) were added in 20 μL 100 mM phosphate buffer (all pH
between 7.0 and 8.0) immediately before addition of the
radiotracer.
For [18F]FEMAET efﬂux experiments, PC-3 cells were incu-
bated with tracer as described above for 60 min and washed twice
with ice cold EBSS before 400 μl EBSS containing 800 μM
L-leucine, 10 mM L-lysine or the respective volume of EBSS (all pH
between 7.0 and 8.0) was added (time zero). The plates were incubated
at 37 °C, and cells were washed twice with the respective ice cold
incubation solution at the indicated time points, detached and analysed
as described above.
Expression Levels of ATB0,+ in Cultured Cells
and Xenografts
Total RNA was isolated from PC-3, NCI-H69 and MDA-MB-231
(American Type Culture Collection) cell lines and the respective
xenografts according to the protocols of the Isol-RNA Lysis
Reagent (5 PRIME) and the bead-milling TissueLyser system
(Qiagen). QuantiTect® Reverse Transcription Kit (Qiagen) was
used to generate cDNA. The following primers (Microsynth) were
used for the polymerase chain reaction (PCR): human beta-actin
(ACTB), forward 5′-CATGTACGTTGCTATCCAGGC-3′, reverse
5′-CTCCTTAATGTCACGCACGAT-3′ and human ATB0,+
(SLC6A14), forward 5′-TGGGGTCCATACCTGGAACA-3′, re-
verse 5′-TGCTGCCACTAACAGTAGGT-3′. Quantitation of
ATB0,+ expression was performed with the DyNAmoTM Flash
SYBR® Green qPCR Kit (Thermo Scientiﬁc) using a 7900 HT Fast
Real-Time PCR System (Applied Biosystems). The ampliﬁcation
signals were detected in real-time, which permitted accurate
quantiﬁcation of the amounts of the initial RNA template during
40 cycles according to the manufacturer's protocol. All reactions
were performed in duplicates and within three independent runs.
Quantitative analysis was performed using the SDS Software (v2.4)
and a previously described 2-ΔΔCt quantiﬁcation method [15]. The
speciﬁcity of the PCR products of each run was determined and
veriﬁed with the SDS dissociation curve analysis feature.
PET with Xenograft-Bearing Mice
Animal care and experiments were conducted in compliance with
Swiss Animal Welfare legislation and have been approved by the
Veterinary Ofﬁce of the Canton Zurich, Switzerland. Six weeks old
female NMRI nu/nu mice from Charles River, Sulzfeld (Germany)
were inoculated with 2×106 PC-3 cells in 0.1 ml PBS/matrigel 1:1
(Invitrogen; BP Biosciences) or 2×106 MDA-MB-231 cells in
0.1 ml matrigel subcutaneously on the right shoulder. For NCI-H69
xenografts, mice were inoculated with 107 NCI-H69 cells in 0.1 ml
PBS subcutaneously on the right shoulder and 1 week later with the
same cell number in matrigel on the left shoulder. Xenografts were
grown for several weeks until they reached 0.5 to 1.5 cm3. Mice
had free access to food and water. For dynamic scans from 1 to
90 min post injection (p.i.), one mouse with a PC-3 and one with an
MDA-MB-231 xenograft were injected under anaesthesia (2–3 %
isoﬂurane in oxygen/air) with 13 and 15 MBq [18F]FEMAET,
respectively, in 0.1 ml formulation into a tail vein and a dynamic
PET scan (Vista eXplore, Sedecal, Spain, axial ﬁeld of view
4.8 cm) was started about 1 min later. For dynamic scans from 60
to 150 min (one mouse each with a PC-3 and MDA-MB-231
xenograft) and static scans from 60 to 90 min (six NCI-H69
xenograft-bearing mice for the inhibition study with αMTRP), mice
were injected awake in a restraining tube with 5.6 to 14 MBq
Fig. 2. Structure of [18F]FEMAET.
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[18F]FEMAET as described above. Anaesthesia was induced
10 min before PET acquisition. In static scans, anterior and
posterior body parts were scanned for 15 min each, starting with
the anterior part. In the inhibition study, NCI-H69 xenograft-
bearing mice were injected 100 mg/kg αMTRP in 100 mM
phosphate buffer pH 7.4 (5 mg αMTRP per ml) intraperitoneally
15 min before intravenous [18F]FEMAET injection. Control
animals were injected the same volume vehicle only. During all
scans, respiratory rate and body temperature were monitored and
controlled between 50 and 70 beats per minute and 36 and 37 °C by
adjusting the isoﬂurane dose and with 37 °C warm air, respectively.
The PET scans were followed by a CT for anatomical orientation.
PET data was reconstructed by 2-dimensional ordered subsets
expectation maximisation and analysed with PMOD 3.4 (PMOD,
Zürich, Switzerland). Volumes of interest (VOI) were delineated
with help of the CT and PET images and standardised uptake
values (SUV) were calculated for the VOIs as the ratio of regional
averaged radioactivity in becquerel per cubic centimetre and
injected radioactivity in becquerel per gram body weight. Radio-
activity was decay-corrected for all calculations. SUV ratios in the
inhibition study with αMTRP were compared by a two-tailed
homoscedastic t test.
Results
Cell Uptake and Efﬂux Studies
As a cationic amino acid, [18F]FEMAET may be transported
by the exchange transporters CATs, y+LAT2 and b0,+AT or
the concentrative transporter ATB0,+ but not by LAT1/2
(Fig. 1) [16]. We have recently shown uptake of
[18F]FEMAET into NCI-H69 small cell lung cancer cells
in vitro and in vivo and suspected transport by ATB0,+ as the
primary uptake mechanism [14]. In this work, we investi-
gated the mechanism of cell uptake of [18F]FEMAET in
more detail. To verify transport by ATB0,+, we studied the
effect of αMTRP, an inhibitor of ATB0,+ (and LAT1) on
[18F]FEMAET uptake in NCI-H69 cells. As shown in
Fig. 3a, 1 mM αMTRP inhibited uptake by 965 % at
37 °C and to ~30 % at 4 °C after 30 min incubation, the time
point when uptake at 37 °C approached a plateau under
identical experimental conditions [14].
Figure 3b shows [18F]FEMAET accumulation in prostate
cancer PC-3 cells at 37 °C, reaching 8.8±1.6 % uptake per
mg protein at 60 min (n=10). Uptake at 4 °C was
signiﬁcantly lower with 1.9±1.0 %/mg. Figure 3c shows
the effects of the (LAT1/2 and) ATB0,+ inhibitor BCH [10,
16, 17] and natural amino acids with basic side chains on
[18F]FEMAET uptake into PC-3 cells. BCH reduced
[18F]FEMAET uptake by more than 90 %. The cationic
dibasic amino acids L-arginine and L-lysine, inﬂux substrates
of CATs, y+LAT2, b0,+AT and ATB0,+ [10, 13, 17] as well
as the neutral dibasic L-histidine, inﬂux substrate at
physiological pH of LATs [18] and ATB0,+ [10, 13] reduced
[18F]FEMAET uptake, though to a lower extent than BCH.
Extracellular stimulation of an exchange transporter
accelerates efﬂux of its substrates [16]. Figure 3d shows
depletion within 5 min of the LAT substrate [18F]FDOPA
from PC-3 cells after addition of 800 μM L-leucine. A
similar rapid depletion was observed for the LAT substrate
[18F]FEHTP [6]. We expected that a selective ATB0,+
substrate would not be recognised by exchange transporters.
Extracellular amino acids should, therefore, not accelerate its
efﬂux as tremendously as observed for the LAT1/2
substrates. As shown in Fig. 3e, f, both 800 μM of the
LAT substrate L-leucine and 10 mM of the cationic amino
acid L-lysine had only moderate effects on the efﬂux of
[18F]FEMAET from PC-3 cells as compared to its efﬂux in
the absence of stimulation. At 30 min after stimulation,
radioactivity in cells was 950 % of the control without
stimulation. Based on the above results, we hypothesised
that transport by ATB0,+ is the primary mechanism for
[18F]FEMAET uptake.
Expression of ATB0,+ in NCI-H69, PC-3
and MDA-MB-231 Cells and Xenografts
As mentioned in the “Introduction”, not all cancers
overexpress ATB0,+. We conﬁrmed expression of the
transporter in both PC-3 and NCI-H69 cell lines by real-
time PCR (Fig. 4). As shown by Karunakaran et al. [9], we
did not ﬁnd signiﬁcant expression of ATB0,+ in MDA-MB-
231 breast cancer cells. Based on our real-time PCR analysis
and cell uptake experiments, we proceeded with in vivo PET
studies with PC-3, NCI-H69 and MDA-MB-231 xenograft-
bearing mice, expecting uptake of [18F]FEMAET into PC-3
besides NCI-H69 [14] xenografts but negligible uptake into
the ATB0,+-negative MDA-MB-231 xenografts. In agree-
ment with the analysis of the cultured cells, ATB0,+ was
signiﬁcantly expressed in PC-3 and NCI-H69 but not in
MDA-MB-231 xenografts, as determined by real-time PCR
(Fig. 4).
PET Studies with Mice Bearing ATB0,+-Positive
and ATB0,+-Negative Xenografts and Inhibition
of Uptake by αMTRP
Figure 5 shows PET images of PC-3 (ATB0,+-positive) and
MDA-MD-231 (ATB0,+-negative) xenograft-bearing mice
averaged from 60 to 90 min and from 120 to 150 min,
respectively, after [18F]FEMAET administration. The corre-
sponding time–activity curves (TACs) and radioactivity ratios
between PC-3 xenografts and opposite shoulder are shown in
Fig. 6. [18F]FEMAET accumulated in PC-3 xenografts. The
SUV ratio between xenograft and opposite shoulder reached 2.5
towards the end of the 60–150 min scan. As expected, no or
only negligible accumulation was observed in the ATB0,+-
negative MDA-MB-231 xenografts.
Finally, we investigated whether [18F]FEMAET uptake
into ATB0,+-positive NCI-H69 xenografts can be inhibited
by an ATB0,+ inhibitor. Application of 100 mg/kg αMTRP
signiﬁcantly reduced the SUV ratio between NCI-H69
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xenografts and neck region from 2.11±0.38 to 1.67±0.18
(averaged from 60 to 75 min p.i.; n=5 xenografts of three
baseline mice and six xenografts of three blocked mice,
respectively, pG0.05). Note that the PET image shown in
[14] is from one of the baseline scans.
Discussion
We have recently introduced the cationic amino acid PET
probe [18F]FEMAET and have shown uptake into NCI-H69
small cell lung cancer cells in vitro and xenografts in mice
[14]. Transport systems that promote cell uptake of cationic
amino acids are CATs, y+LATs, b0,+AT and ATB0,+ (Fig. 1).
Here, we provide strong evidence that [18F]FEMAET is
selectively targeting the amino acid transporter ATB0,+,
which is upregulated in several cancer types and is under
investigation as a drug target for anticancer therapy [9]. As
concluded from the relatively low uptake ratios between
xenografts and reference tissue, [18F]FEMAET will not
compete with other amino acid tracers such as [18F]FET or
anti-[18F]FACBC for tumour imaging in general. However,
[18F]FEMAET allows to evaluate the expression and activity
of ATB0,+, a feature which could advance the development
and support the clinical use of ATB0,+-targeting drugs.
Fig. 3. a Uptake of [18F]FEMAET into NCI-H69 cells after 30 min at 37 and 4 °C and inhibition by 1 mM αMTRP (MTRP).
Averages of two independent experiments each normalised to uptake %/mg protein at 37 °C. Error bars indicate values of the
single experiments. The complete time course of [18F]FEMAET uptake in NCI-H69 cells without αMTRP is shown elsewhere
[14]. b Uptake of [18F]FEMAET into PC-3 cells at 37 °C (white square) and 4 °C (white circle). c PC-3 cells were incubated with
[18F]FEMAET for 60 min at 37 °C in the absence of other amino acids (-) or together with 10 mM BCH, L-arginine (Arg), L-lysine
(Lys) or L-histidine (His). Uptake was normalised to %/mg without inhibitor. Error bars indicate standard deviations (n≥3). d–f
PC-3 cells were incubated with [18F]FDOPA (d) or [18F]FEMAET (e, f) for 60 min at 37 °C before trans-stimulation. d Efflux of
[18F]FDOPA after trans-stimulation with 800 μM L-leucine (white circle, n=2) or without trans-stimulation (control, white square,
n=3) at 37 °C. Error bars indicate standard deviations (control) or the values of the single experiments (L-leucine). e, f Efflux of
[18F]FEMAET with (white circle) and without (control, white square) trans-stimulation by 800 μM L-leucine (Leu) (e) and 10 mM L-
lysine (Lys) (f), one experiment each. Most data in panel d were published before [6].
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Evidence for selective ATB0,+ targeting by [18F]FEMAET
comes from in vitro cell experiments and in vivo PET studies.
[18F]FEMAET uptake into PC-3 (this work) and NCI-H69 cells
(this work and [14]) in vitro was signiﬁcant at 37 °C but low at
4 °C, indicating that transport is energy dependent. This is
expected for ATB0,+ transport, which is driven by the membrane
potential [1, 12]. BCH, a substrate and competitive inhibitor of
LAT1/2 and ATB0,+ reduced uptake into PC-3 cells in vitro by
990 %. Transport by LAT1 or LAT2 can be excluded based on
the fact that [18F]FEMAET is cationic at physiological pH while
LAT1 and LAT2 only recognise net neutral amino acids as
substrates for transport [16]. The known competitive inhibitors of
ATB0,+, L-arginine, L-lysine and L-histidine [13], all reduced
[18F]FEMAET uptake at 10 mM.
The efﬂux of the LAT1/2 substrates [18F]FDOPA and
[18F]FEHTP [6] from PC-3 and NCI-H69 cells was strongly
accelerated by the addition of the LAT1/2 substrate L-leucine
to the cells. Only moderate acceleration of [18F]FEMAET
efﬂux was observed after trans-stimulation with the same
concentration of L-leucine and with L-lysine. L-Leucine
activates efﬂux of neutral amino acids by LAT1/2 and
cationic amino acids by y+LAT1/2 [16, 19]. L-Lysine
activates efﬂux of neutral amino acids by b0,+AT and
cationic amino acids by y+LAT2 and CAT1 [16]. Based on
the weak effect of trans-stimulation on [18F]FEMAET
efﬂux, we conclude that none of these exchange transporters
recognises [18F]FEMAET as a substrate neither for uptake
nor for efﬂux.
Fig. 4. Quantitative real-time PCR. ATB0,+ expression levels
were quantified relative to beta-actin in the indicated cancer
cell lines and xenografts. Average ± standard error.
Fig. 5. PET/CT images of xenograft-bearing mice after [18F]FEMAET administration. a, b ATB0,+-positive PC-3 xenografts; c, d
ATB0,+-negative MDA-MB-231 xenografts. a, c Averaged from 60 to 90 min p.i.; b, d averaged from 120 to 150 min p.i. Arrows
indicate xenografts. MIP maximal intensity projection. Colour scale, PET SUV; white/grey CT. SUV scales were adjusted to
result in similar colour (blue) for background tissue in all images.
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More evidence for ATB0,+ transport comes from the
uptake inhibition in NCI-H69 cells by 1 mM of the LAT and
ATB0,+ transport inhibitor αMTRP by up to 66 %. For
comparison, Karunakaran et al. found 80 % inhibition of
glycine transport at the same αMTRP concentration in
ATB0,+-transfected oocytes [13]. IC50 was estimated to
0.25 mM [13]. Note that the transporter is thus not fully
saturated at 1 mM αMTRP. Besides the in vitro experiments,
the PET studies strongly supported our hypothesis that
[18F]FEMAET accumulates in cancer cells by ATB0,+
transport. First, the ATB0,+ inhibitor αMTRP reduced
tumour uptake of [18F]FEMAET. Assuming homogenous
distribution of the inhibitor in body water, the 100 mg/kg
dose resulted in a maximal concentration of ≤0.7 mM,
decreasing with time. No complete transport inhibition can
be expected at this dose, considering the IC50 of 0.25 mM.
Nevertheless, we found signiﬁcant reduction in tumour/
reference tissue ratio after αMTRP application. Second,
[18F]FEMAET did not accumulate in the ATB0,+-negative
MDA-MB-231 xenografts. Finally, in contrast to LAT1
substrates, [18F]FEMAET was excluded from the brain after
intravenous administration in mouse [14]. This would be
expected for a substrate of ATB0,+ such as [18F]FEMAET,
as ATB0,+ is absent in the brain [10] and as amino acids, in
general, require a transport system to cross the blood–brain
barrier. Altogether, our data strongly supports our hypothesis
that ATB0,+ transport is the major mechanism of
[18F]FEMAET uptake into cancer cells in vitro and in vivo.
Further studies with transporter expression systems and/or
targeted silencing of transporters with, e.g. siRNA will
reveal the extent of contribution of alternative transport
systems to [18F]FEMAET cell uptake.
We assign selectivity for ATB0,+ transport to the
following structure characteristics: (a) The tertiary amine of
the amino acid side chain renders [18F]FEMAET cationic at
physiological pH with an expected pKa between 10 and 11
[20]. This impedes recognition by transport systems for
neutral amino acids such as LAT. (b) ATB0,+ has a less
Fig. 6. TACs (a, b, e, f) and radioactivity ratios (c, d) from the [18F]FEMAET PET scans shown in Fig. 5. a, c, e 0–90 min scans;
b, d, f 60–150 min scans. a, b PC-3 mice, xenograft (white circle), opposite shoulder (white square), kidney (white diamond in
insert), liver (white triangle), brain (multiplication sign). c, d Corresponding xenograft-to-tissue ratios (symbols of tissues as in a,
b, e, f) TACs with MDA-MB-231 mice. Symbols as in a and b.
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restrictive recognition pattern than the other amino acid
transport systems. The non-natural amino acid structure
of [18F]FEMAET may exclude recognition by other
transporters than ATB0,+. (c) The metabolic stability of
[18F]FEMAET in vivo and in human microsomes ex-
cludes accumulation via a biotransformation step [14].
We modiﬁed tyrosine by ether coupling to the 5-hydroxy
group rather than by an ester or amide bond at a
carboxyl group as suggested for pro-drug design [11]. In
contrast to pro-drugs, hydrolysis of the PET probe was not
desired.
We are not aware of any other basic and cationic amino
acid that is currently in use or under investigation for PET
imaging. A promising new amino acid PET probe with a
basic side chain, the triazole (S)-2-amino-3-[1-(2-
[18F]ﬂuoroethyl)-1H-[1–3]triazol-4-yl]propanoic acid
([18F]AFETP), was recently introduced by the group of
McConathy [21, 22]. In contrast to [18F]FEMAET, the side
chain with the substituted 1H-[1–3]-triazole is only weakly
basic and is most probably neutral at physiological pH [20,
23, 24]. Cell uptake of [18F]AFETP was reduced by the
same natural amino acids as we found for [18F]FEMAET but
in contrast to [18F]FEMAET only to 31 % by the ATB0,+
and LAT1/2 inhibitor BCH. The authors concluded that
[18F]AFETP must be recognised by more than one amino
acid transport system [22].
Expression of ATB0,+ is upregulated in oestrogen-
sensitive breast cancer, in carcinoma of the cervix and
colorectal cancer [9, 25, 26]. In addition, several oestrogen
receptor positive cancer cell lines express ATB0,+ [9, 13].
This is not surprising as the SLC6A14 (ATB0,+) promoter
contains several putative binding domains for the oestrogen
receptors [9]. PC-3 cells as many other prostate cancer cells
have high expression levels of the oestrogen receptors [27].
ATB0,+ upregulation is, therefore, likely in these and other
prostate cancer cells. We have conﬁrmed its expression in
the PC-3 cell line. Interestingly, we also found high
expression in NCI-H69 cells which lack oestrogen, proges-
terone and androsterone receptors and have only low levels
of glucocorticoid receptor [28]. This indicates that a high
level of oestrogen receptor is not a prerequisite for ATB0,+
overexpression. Besides oestrogen receptor-mediated induc-
tion, protein kinase C increases ATB0,+ activity in cancer
cells [29].
ATB0,+ expression levels in most healthy tissues are
relatively low [9, 25, 26]. This together with its concentra-
tive transport mechanism and its broad substrate speciﬁcity
makes ATB0,+ a good target for anticancer therapy [9, 13]
and drug and pro-drug delivery [12]. ATB0,+ could thus
become of interest as a target for non-invasive imaging to
advance the development of ATB0,+-targeting drugs and in
the context of tumour characterisation for therapy planning
and therapy monitoring. Regarding drug development,
[18F]FEMAET PET could help evaluating the in vivo
potency of ATB0,+ inhibitors as well as the transport
efﬁciency of ATB0/+-targeting drugs and pro-drugs.
We used L-tyrosine for [18F]FEMAET synthesis but did
not conﬁrm the stereochemistry of the ﬁnal product [14]. In
general, ATB0,+ recognises both L- and D-amino acids [12].
However, we cannot exclude that transport kinetics differ
signiﬁcantly between the two isomers. We have recently
discussed the inﬂuence of stereochemistry on PET imaging
with amino acid derivatives in more detail [30]. Further
evaluation, including synthesis and conﬁrmation of
stereochemically pure enantiomers is required to address
this question for [18F]FEMAET.
Conclusions
The cationic amino acid PET probe [18F]FEMAET is most
probably selectively targeting ATB0,+, a concentrative amino
acid transporter that is under preclinical evaluation for
anticancer therapy and as a target for drug and pro-drug
delivery. As [18F]FEMAET uptake into xenografts is reduced
by ATB0,+ inhibition, the probe may serve to characterise
potential ATB0,+ inhibitors and substrates for anticancer
therapy. In the long range, [18F]FEMAET PET may be used
to identify patients that could beneﬁt from ATB0,+-targeted
anticancer therapy and to monitor therapy effects.
Acknowledgments.We thank Romana Meletta for the technical help with the
RNA isolation and cDNA preparation.
Conﬂict of Interest. The authors declare that they have no conﬂict of
interest.
References
1. Ganapathy V, Thangaraju M, Prasad PD (2009) Nutrient transporters in
cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther
121:29–40
2. Jadvar H, Alavi A, Gambhir SS (2009) 18F-FDG uptake in lung, breast,
and colon cancers: molecular biology correlates and disease character-
ization. J Nucl Med 50:1820–1827
3. Bodoy S, Fotiadis D, Stoeger C et al (2012) The small SLC43 family:
facilitator system L amino acid transporters and the orphan EEG1. Mol
Aspects Med 34:638–645
4. Neels OC, Koopmans KP, Jager PL et al (2008) Manipulation of [11C]-
5-hydroxytryptophan and 6-[18F]ﬂuoro-3,4-dihydroxy-L-phenylalanine
accumulation in neuroendocrine tumor cells. Cancer Res 68:7183–7190
5. Langen KJ, Hamacher K, Weckesser M et al (2006) O-(2-
[18F]ﬂuoroethyl)-L-tyrosine: uptake mechanisms and clinical applica-
tions. Nucl Med Biol 33:287–294
6. Krämer SD, Mu L, Müller A et al (2012) 5-(2-18F-ﬂuoroethoxy)-L-
tryptophan as a substrate of system L transport for tumor imaging by
PET. J Nucl Med 53:434–442
7. Sorensen J, Owenius R, Lax M, Johansson S (2013) Regional
distribution and kinetics of [18F]ﬂuciclovine (anti-[18F]FACBC), a
tracer of amino acid transport, in subjects with primary prostate cancer.
Eur J Nucl Med Mol Imaging 40:394–402
8. Okudaira H, Nakanishi T, Oka S et al (2013) Kinetic analyses of trans-
1-amino-3-[18F]ﬂuorocyclobutanecarboxylic acid transport in Xenopus
laevis oocytes expressing human ASCT2 and SNAT2. Nucl Med Biol
40:670–675
9. Karunakaran S, Ramachandran S, Coothankandaswamy V et al (2011)
SLC6A14 (ATB0,+) protein, a highly concentrative and broad speciﬁc
amino acid transporter, is a novel and effective drug target for treatment
of estrogen receptor-positive breast cancer. J Biol Chem 286:31830–
31838
A. Müller et al.: [18F]FEMAET to Image ATB0,+ Activity by PET 419
10. Sloan JL, Mager S (1999) Cloning and functional expression of a
human Na+- and Cl−-dependent neutral and cationic amino acid
transporter B0+. J Biol Chem 274:23740–23745
11. Hatanaka T, Haramura M, Fei YJ et al (2004) Transport of amino acid-
based prodrugs by the Na+- and Cl−-coupled amino acid transporter
ATB0,+ and expression of the transporter in tissues amenable for drug
delivery. J Pharmacol Exp Ther 308:1138–1147
12. Ganapathy ME, Ganapathy V (2005) Amino acid transporter ATB0,+ as
a delivery system for drugs and prodrugs. Curr Drug Targets Immune
Endocr Metabol Disord 5:357–364
13. Karunakaran S, Umapathy NS, Thangaraju M et al (2008) Interaction of
tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of
the transporter as a drug target for cancer chemotherapy. Biochem J
414:343–355
14. Chiotellis A,Müller A,WeyermannK, et al. (2013) Synthesis and preliminary
biological evaluation of O-2((2-[18F]ﬂuoroethyl)methylamino)ethyltyrosine
([18F]FEMAET) as a possible cationic amino acid PET tracer for tumor
imaging (submitted)
15. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T))
Method. Methods 25:402–408
16. Verrey F, Closs EI, Wagner CA et al (2004) CATs and HATs: the
SLC7 family of amino acid transporters. Pﬂug Arch Eur J Physiol
447:532–542
17. Deves R, Boyd CA (1998) Transporters for cationic amino acids in animal
cells: discovery, structure, and function. Physiol Rev 78:487–545
18. Kanai Y, Segawa H, Miyamoto K et al (1998) Expression cloning and
characterization of a transporter for large neutral amino acids activated
by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273:23629–
23632
19. Kanai Y, Fukasawa Y, Cha SH et al (2000) Transport properties of a
system y+L neutral and basic amino acid transporter. Insights into the
mechanisms of substrate recognition. J Biol Chem 275:20787–20793
20. Comer JEA (2007) Ionization constants and ionization proﬁles. In: Van
de Waterbeemd H, Testa B (eds) Comprehensive medicinal chemistry
II. Elsevier, Oxford, pp 357–397
21. McConathy J, Zhou D, Shockley SE et al (2010) Click synthesis and
biologic evaluation of (R)- and (S)-2-amino-3-[1-(2-[18F]ﬂuoroethyl)-
1H-[1,2,3]triazol-4-yl]propanoic acid for brain tumor imaging with
positron emission tomography. Mol Imaging 9:329–342
22. Sai KKS, Huang C, Yuan L et al (2013) 18F-AFETP, 18F-FET, and 18F-
FDG imaging of mouse DBT gliomas. J Nucl Med 54:1120–1126
23. Ryazanova OA, Voloshin IM, Makitruk VL et al (2007) pH-induced
changes in electronic absorption and ﬂuorescence spectra of phenazine
derivatives. Spectrochim Acta A Mol Biomol Spectrosc 66:849–859
24. Tomé AC (2004) Product class 13: 1,2,3-triazoles. In: Stor R, Gilchrist
T (eds) Science of synthesis, vol 13. Georg Thieme, Stuttgart, pp 415–
601
25. Gupta N, Miyauchi S, Martindale RG et al (2005) Upregulation of the
amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and
metastasis in humans. Biochim Biophys Acta 1741:215–223
26. Gupta N, Prasad PD, Ghamande S et al (2006) Up-regulation of the
amino acid transporter ATB0,+ (SLC6A14) in carcinoma of the cervix.
Gynecol Oncol 100:8–13
27. Pandini G, Genua M, Frasca F et al (2007) 17beta-estradiol up-regulates
the insulin-like growth factor receptor through a nongenotropic pathway
in prostate cancer cells. Cancer Res 67:8932–8941
28. Kaiser U, Hofmann J, Schilli M et al (1996) Steroid-hormone receptors
in cell lines and tumor biopsies of human lung cancer. Int J Cancer
67:357–364
29. Samluk L, Czeredys M, Skowronek K, Nalecz KA (2012) Protein
kinase C regulates amino acid transporter ATB0,+. Biochem Biophys
Res Commun 422:64–69
30. Chiotellis A, Mu L, Müller A et al (2013) Synthesis and biological
evaluation of 18F-labeled ﬂuoropropyl tryptophan analogues as potential
PET probes for tumor imaging. Eur J Med Chem 70C:768–780
420 A. Müller et al.: [18F]FEMAET to Image ATB0,+ Activity by PET
